The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

‘GABA Factory’ Probiotic LP815® Improves Sleep and Reduces Stress
Biotics and Supplements

‘GABA Factory’ Probiotic LP815® Improves Sleep and Reduces Stress

JAN 22, 2026
EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS
Clinical & Manufacturing

EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS

JAN 8, 2026
AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244
Pharma & Human Health

AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244

DEC 9, 2025
UC San Diego researchers develop new tool to predict how bacteria influence health
Pharma & Human Health

UC San Diego researchers develop new tool to predict how bacteria influence health

NOV 28, 2025
Traces of bacteria inside brain tumors may affect tumor behavior
Gut-Brain Axis

Traces of bacteria inside brain tumors may affect tumor behavior

NOV 24, 2025
Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select
Clinical & Manufacturing

Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select

NOV 19, 2025
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Clinical & Manufacturing

Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study

NOV 17, 2025
Ferring Presents New Data Analyses for REBYOTA®
Infectious Disease & AMR

Ferring Presents New Data Analyses for REBYOTA®

NOV 4, 2025
Ascribe Bio Closes $12 Million Series A Financing to Advance Next-Generation Natural Crop Protection
Finance

Ascribe Bio Closes $12 Million Series A Financing to Advance Next-Generation Natural Crop Protection

NOV 3, 2025
Seres Therapeutics Receives Award of up to $3.6M from Carb-X to Develop Liquid Formulation of Ser-155
Finance

Seres Therapeutics Receives Award of up to $3.6M from Carb-X to Develop Liquid Formulation of Ser-155

OCT 31, 2025
Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis
Clinical & Manufacturing

Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis

OCT 29, 2025